MX2011007779A - Formulaciones galenicas de compuestos organicos. - Google Patents
Formulaciones galenicas de compuestos organicos.Info
- Publication number
- MX2011007779A MX2011007779A MX2011007779A MX2011007779A MX2011007779A MX 2011007779 A MX2011007779 A MX 2011007779A MX 2011007779 A MX2011007779 A MX 2011007779A MX 2011007779 A MX2011007779 A MX 2011007779A MX 2011007779 A MX2011007779 A MX 2011007779A
- Authority
- MX
- Mexico
- Prior art keywords
- core
- tablet
- organic compounds
- outer coating
- dosage form
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000003826 tablet Substances 0.000 abstract 3
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 abstract 1
- 229960004601 aliskiren Drugs 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 230000000873 masking effect Effects 0.000 abstract 1
- 239000008185 minitablet Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000007892 solid unit dosage form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente solicitud se refiere a una forma de dosificación unitaria sólida para su administración oral en la forma de una tableta que tiene un núcleo y un recubrimiento externo, en donde: - el núcleo de la tableta comprende una cantidad terapéuticamente efectiva de Alisquireno, o de una sal farmacéuticamente aceptable del mismo, y - el recubrimiento externo está en la forma de un recubrimiento de película, el cual tiene propiedades enmascaradoras de sabor y/o una funcionalidad de liberación controlada. De preferencia, la tableta de núcleo es parte de un sistema de múltiples partículas, en particular una minitableta. La forma de dosificación oral sólida es en particular adecuada para uso pediátrico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09151496 | 2009-01-28 | ||
| PCT/EP2010/050886 WO2010086312A1 (en) | 2009-01-28 | 2010-01-27 | Galenic formulations of organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011007779A true MX2011007779A (es) | 2011-08-12 |
Family
ID=40770648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011007779A MX2011007779A (es) | 2009-01-28 | 2010-01-27 | Formulaciones galenicas de compuestos organicos. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20110287100A1 (es) |
| EP (1) | EP2391345B1 (es) |
| JP (1) | JP2012516299A (es) |
| KR (1) | KR20110117199A (es) |
| CN (1) | CN102300558A (es) |
| AR (1) | AR075179A1 (es) |
| AU (1) | AU2010209787B2 (es) |
| BR (1) | BRPI1007452A2 (es) |
| CA (1) | CA2749531A1 (es) |
| CL (1) | CL2011001817A1 (es) |
| CO (1) | CO6400184A2 (es) |
| EC (1) | ECSP11011289A (es) |
| ES (1) | ES2525648T3 (es) |
| IL (1) | IL213918A0 (es) |
| MA (1) | MA33060B1 (es) |
| MX (1) | MX2011007779A (es) |
| MY (1) | MY153852A (es) |
| NZ (1) | NZ593622A (es) |
| PE (1) | PE20110943A1 (es) |
| PL (1) | PL2391345T3 (es) |
| PT (1) | PT2391345E (es) |
| RU (1) | RU2535090C2 (es) |
| SG (1) | SG172226A1 (es) |
| TN (1) | TN2011000307A1 (es) |
| TW (1) | TWI468191B (es) |
| WO (1) | WO2010086312A1 (es) |
| ZA (1) | ZA201104489B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5822758B2 (ja) * | 2011-03-02 | 2015-11-24 | 第一三共ヘルスケア株式会社 | 速溶性防湿フィルムコーティング製剤及びその製造方法 |
| EP2596802A1 (en) * | 2011-11-23 | 2013-05-29 | PLS-Design GmbH | Pharmaceutical composition for treatment of allergic reactions |
| PT3411021T (pt) * | 2016-02-03 | 2025-08-06 | Novartis Ag | Nova utilização de uma combinação de sacubitril e valsartan |
| US12171878B2 (en) | 2018-08-10 | 2024-12-24 | Kissei Pharmaceutical Co., Ltd. | Sucroferric oxyhydroxide-containing granules and pharmaceutical composition |
| JP7681511B2 (ja) | 2019-02-22 | 2025-05-22 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | インライン混合中の懸濁液の通気の最小化 |
| BR112021016485A2 (pt) | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos |
| GB2597578B (en) | 2019-02-22 | 2023-04-26 | Catalent Uk Swindon Zydis Ltd | Preserving functionally-coated API particles produced by solventless mixing processes in aqueous suspension |
| BR112021016421A2 (pt) | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aglomeração, aeração e preservação do revestimento de composições farmacêuticas que compreendem ibuprofeno |
| WO2021011538A1 (en) * | 2019-07-15 | 2021-01-21 | R.P. Scherer Technologies, Llc | Capsule dosage forms, methods of preparation and methods of use thereof |
| AR123109A1 (es) | 2020-07-31 | 2022-10-26 | Catalent Uk Swindon Zydis Ltd | Composiciones farmacéuticas que comprenden ifa |
| EP4255495A4 (en) | 2020-12-03 | 2025-10-08 | Battelle Memorial Institute | COMPOSITIONS OF POLYMERIC NANOPARTICLES AND DNA NANOSTRUCTURES AND METHODS FOR NON-VIRAL DELIVERY |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025105451A1 (ja) * | 2023-11-17 | 2025-05-22 | 第一三共ヘルスケア株式会社 | 固形製剤 |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
| DE19842753A1 (de) * | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| AR034813A1 (es) * | 2001-07-20 | 2004-03-17 | Novartis Ag | Composiciones farmaceuticas y uso de las mismas |
| US20040266743A1 (en) * | 2003-05-09 | 2004-12-30 | Pharmacia Corporation | Combination of an aldosterone receptor antagonist and a renin inhibitor |
| MY144477A (en) | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
| US20070224260A1 (en) * | 2004-04-15 | 2007-09-27 | Dr. Reddy's Laboratories Limited | Dosage Form Having Polymorphic Stability |
| ES2384637T3 (es) * | 2004-10-08 | 2012-07-10 | Novartis Ag | Uso de inhibidores de la renina para la prevención o el tratamiento de disfunción diastólica o insuficiencia cardiaca diastólica |
| ES2364538T3 (es) * | 2007-09-28 | 2011-09-06 | Novartis Ag | Combinación farmacéutica de alisquireno y valsartán. |
-
2010
- 2010-01-27 WO PCT/EP2010/050886 patent/WO2010086312A1/en not_active Ceased
- 2010-01-27 SG SG2011044450A patent/SG172226A1/en unknown
- 2010-01-27 CN CN2010800057033A patent/CN102300558A/zh active Pending
- 2010-01-27 MY MYPI2011003186A patent/MY153852A/en unknown
- 2010-01-27 AU AU2010209787A patent/AU2010209787B2/en not_active Ceased
- 2010-01-27 JP JP2011546822A patent/JP2012516299A/ja active Pending
- 2010-01-27 US US13/145,454 patent/US20110287100A1/en not_active Abandoned
- 2010-01-27 KR KR1020117019809A patent/KR20110117199A/ko not_active Ceased
- 2010-01-27 ES ES10702092.7T patent/ES2525648T3/es active Active
- 2010-01-27 PE PE2011001391A patent/PE20110943A1/es not_active Application Discontinuation
- 2010-01-27 PT PT107020927T patent/PT2391345E/pt unknown
- 2010-01-27 NZ NZ593622A patent/NZ593622A/en not_active IP Right Cessation
- 2010-01-27 MX MX2011007779A patent/MX2011007779A/es not_active Application Discontinuation
- 2010-01-27 CA CA2749531A patent/CA2749531A1/en not_active Abandoned
- 2010-01-27 RU RU2011135417/15A patent/RU2535090C2/ru not_active IP Right Cessation
- 2010-01-27 MA MA34114A patent/MA33060B1/fr unknown
- 2010-01-27 AR ARP100100193A patent/AR075179A1/es unknown
- 2010-01-27 BR BRPI1007452A patent/BRPI1007452A2/pt not_active IP Right Cessation
- 2010-01-27 PL PL10702092T patent/PL2391345T3/pl unknown
- 2010-01-27 TW TW99102290A patent/TWI468191B/zh not_active IP Right Cessation
- 2010-01-27 EP EP10702092.7A patent/EP2391345B1/en not_active Not-in-force
-
2011
- 2011-06-16 TN TN2011000307A patent/TN2011000307A1/fr unknown
- 2011-06-17 ZA ZA2011/04489A patent/ZA201104489B/en unknown
- 2011-07-04 IL IL213918A patent/IL213918A0/en unknown
- 2011-07-27 CL CL2011001817A patent/CL2011001817A1/es unknown
- 2011-07-28 CO CO11095153A patent/CO6400184A2/es not_active Application Discontinuation
- 2011-08-26 EC EC2011011289A patent/ECSP11011289A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TWI468191B (zh) | 2015-01-11 |
| PT2391345E (pt) | 2014-12-03 |
| PE20110943A1 (es) | 2012-01-22 |
| TN2011000307A1 (en) | 2012-12-17 |
| RU2011135417A (ru) | 2013-03-10 |
| EP2391345B1 (en) | 2014-09-03 |
| HK1161125A1 (en) | 2012-08-24 |
| CA2749531A1 (en) | 2010-08-05 |
| CN102300558A (zh) | 2011-12-28 |
| AU2010209787A1 (en) | 2011-07-14 |
| WO2010086312A1 (en) | 2010-08-05 |
| SG172226A1 (en) | 2011-07-28 |
| CO6400184A2 (es) | 2012-03-15 |
| AU2010209787B2 (en) | 2013-06-06 |
| KR20110117199A (ko) | 2011-10-26 |
| MY153852A (en) | 2015-03-31 |
| TW201038300A (en) | 2010-11-01 |
| AR075179A1 (es) | 2011-03-16 |
| ECSP11011289A (es) | 2011-09-30 |
| EP2391345A1 (en) | 2011-12-07 |
| PL2391345T3 (pl) | 2015-03-31 |
| NZ593622A (en) | 2013-12-20 |
| JP2012516299A (ja) | 2012-07-19 |
| CL2011001817A1 (es) | 2012-01-13 |
| MA33060B1 (fr) | 2012-02-01 |
| ES2525648T3 (es) | 2014-12-26 |
| IL213918A0 (en) | 2011-07-31 |
| BRPI1007452A2 (pt) | 2016-02-16 |
| ZA201104489B (en) | 2012-02-29 |
| RU2535090C2 (ru) | 2014-12-10 |
| US20110287100A1 (en) | 2011-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011007779A (es) | Formulaciones galenicas de compuestos organicos. | |
| MY152279A (en) | Immediate release pharmaceutical compositions comprising oxycodone and naloxone | |
| WO2008040534A3 (en) | Non-mucoadhesive film dosage forms | |
| EP4538227A3 (en) | Sodium thiosulfate-containing pharmaceutical compositions | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| NZ589437A (en) | Immediate release tablet comprising 5-azacytidine and a non-enteric coating applied with an ethanol solvent | |
| WO2012007159A3 (en) | Novel gastro-retentive dosage forms | |
| TN2010000135A1 (en) | Galenical formulations of organic compounds | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| MY152951A (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application | |
| WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
| SG141358A1 (en) | Treatment of psychiatric patients with reduced heptaic function with paliperidone | |
| WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| GB2455875B (en) | A process for the preparation of an orally administered unit dose tablet | |
| WO2010044097A3 (en) | Novel dosage form of paliperidone and process for preparing the same | |
| GB0703674D0 (en) | A Process For The Preparation of an Orally Administered Unit Dose Tablet | |
| WO2013098268A3 (en) | Tablets and dry-coated agents | |
| JO3239B1 (ar) | تركيبات جالينية من مركبات عضوية | |
| GB0920721D0 (en) | An orally administered anthelmintic unit dose tablet and process for the preparation thereof | |
| ATE546133T1 (de) | Orale dosierform mit trisubstituierten glycerin- verbindungen | |
| WO2010035245A3 (en) | Extended release dosage form of ropinirole | |
| MX2011009846A (es) | Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |